X

Trial Profile

A phase 1 clinical trial of RNDP-001 in inherited and idiopathic forms of Parkinson's disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 29 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RND 001 (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Therapeutic Use

Most Recent Events

29 Feb 2024 According to a Kenai Therapeutics media release, Ryne Biotechnology has changed its name to Kenai Therapeutics
29 Feb 2024 According to a Kenai Therapeutics media release, the company announced $82 million Series A financing. Proceeds from the financing will enable the Company to submit an IND for RNDP-001 and complete Phase 1 clinical trials, which will initiate within the year.
20 Feb 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com